Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.

Published on Feb 1, 2021in Clinical & Translational Oncology2.737
· DOI :10.1007/S12094-020-02427-2
Giulio Francolini13
Estimated H-index: 13
(UniFI: University of Florence),
Beatrice Detti20
Estimated H-index: 20
(UniFI: University of Florence)
+ 14 AuthorsGianluca Ingrosso13
Estimated H-index: 13
(University of Perugia)
Source
Abstract
AIMS 68Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA   7 (p = 0.004) and TTR < 29.5 months (p = 0.003). CONCLUSIONS PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.
📖 Papers frequently viewed together
35 Citations
4 Citations
9 Citations
References44
Newest
#1Mohsen Beheshti (RWTH Aachen University)H-Index: 4
#1Mohsen Beheshti (Paracelsus Private Medical University of Salzburg)H-Index: 4
Last. Werner Langsteger (St. Vincent's Health System)H-Index: 29
view all 7 authors...
Purpose: The main objective of this prospective study was to determine the impact of multi-phasic acquisition of (68)Ga-PSMA PET/CT in the detection of recurrent prostate cancer (PCa) in the early stage of biochemical recurrence (BR) with prostate-serum-antigen (PSA) level <1ng/ml. Also, (68)Ga-PSMA PET/CT positivity was correlated with clinical parameters for the assessment of predictive markers. Methods: A prospective monocentric study was conducted on 135 PCa patients with BR and PSA<1ng/ml. ...
8 CitationsSource
#1Marlon Perera (UQ: University of Queensland)H-Index: 21
#2Nathan Papa (University of Melbourne)H-Index: 13
Last. Declan G. Murphy (University of Melbourne)H-Index: 107
view all 11 authors...
Abstract Context Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is becoming increasingly more important in guiding local and systemic treatment. Gallium-68 prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has increasingly been utilised globally to assess the local and metastatic burden of prostate cancer, typically in biochemically recurrent or advanced disease. Following our previous meta-analysis, a high-volume series has been repo...
202 CitationsSource
#1Giulio Francolini (UniFI: University of Florence)H-Index: 13
#2Barbara Alicja Jereczek-Fossa (IEO: European Institute of Oncology)H-Index: 36
Last. Lorenzo Livi (UniFI: University of Florence)H-Index: 28
view all 13 authors...
OBJECTIVE: To assess the safety and effectiveness of stereotactic salvage radiotherapy (SSRT) in RT-naive patients affected by macroscopic prostate bed recurrence. PATIENTS AND METHODS: Consecutive patients treated for prostate bed macroscopic recurrence in three different Italian institutes were reviewed. Patients were treated with SSRT, with a total dose of 30-40 Gy in five fractions, the mean pre-SSRT PSA level was 2.3 ng/mL. Two different PSA thresholds were defined and biochemical recurrenc...
3 CitationsSource
Postoperative biochemical recurrence occurs in up to 40% of prostate carcinoma patients treated with radical prostatectomy. Primary tumor grade and cribriform architecture are important parameters for clinical outcome; however, their relevance at positive surgical margins has not been completely elucidated yet. We reviewed 835 radical prostatectomy specimens and recorded pT-stage, surgical margin status, Grade Group, and cribriform architecture of the primary tumor and at positive surgical margi...
6 CitationsSource
#1Cem OnalH-Index: 18
#2Nese Torun (Başkent University)H-Index: 7
Last. Gokhan OzyigitH-Index: 19
view all 9 authors...
: To assess the role of Gallium-labeled-prostate-specific membrane antigen PET/CT (Ga-PSMA-PET/CT) in risk group definition and radiotherapy planning in the initially planned definitive radiotherapy (RT) for prostate cancer patients. METHODS: The clinical data of 191 prostate cancer patients treated with definitive intensity-modulated RT were retrospectively analyzed. All patients were initially staged with thoracoabdominal CT and bone scintigraphy, and the second staging was performed using Ga-...
8 CitationsSource
#1Michael McCarthy (SCGH: Sir Charles Gairdner Hospital)H-Index: 6
#2Roslyn Francis (Harry Perkins Institute of Medical Research)H-Index: 1
Last. Andrew Campbell (Fiona Stanley Hospital)H-Index: 2
view all 5 authors...
Purpose The purpose of this study is to assess the utility of 68Gallium prostate-specific membrane antigen (PSMA) Division of Radiopharmaceutical Chemistry (DKFZ)-PSMA-11 positron emission tomography (PET)–computed tomography (CT), compared with standard imaging, in the detection of recurrent prostate carcinoma in patients with biochemical relapse to determine the prevalence of oligometastatic disease recurrence and its distribution. Methods and Materials This is a prospective, multicenter clini...
23 CitationsSource
#1Nina-Sophie Schmidt-Hegemann (LMU: Ludwig Maximilian University of Munich)H-Index: 11
#2Chukwuka Eze (LMU: Ludwig Maximilian University of Munich)H-Index: 11
Last. Harun Ilhan (LMU: Ludwig Maximilian University of Munich)H-Index: 19
view all 14 authors...
: 68Ga-prostate-specific membrane antigen PET/CT (68Ga-PSMA PET/CT) offers unprecedented accuracy for staging of primary, persistent, or recurrent prostate cancer. Thus, we hypothesized that 68Ga-PSMA PET/CT before radiotherapy significantly affects the radiotherapeutic approach in comparison to the current standard, a CT-based approach. Methods: Between February 2014 and December 2017, 172 patients underwent 68Ga-PSMA PET/CT before radiotherapy and were included in this retrospective analysis. ...
19 CitationsSource
#1Wolfgang P. Fendler (University of Duisburg-Essen)H-Index: 30
#2Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
Last. Thomas A. Hope (UCSF: University of California, San Francisco)H-Index: 39
view all 25 authors...
Importance: In retrospective studies, 68Ga-PSMA-11 positron emission tomographic (PET) imaging improves detection of biochemically recurrent prostate cancer compared with conventional imaging. Objective: To assess 68Ga-PSMA-11 PET accuracy in a prospective multicenter trial. Design, Setting, and Participants: In this single-arm prospective trial conducted at University of California, San Francisco and University of California, Los Angeles, 635 patients with biochemically recurrent prostate cance...
143 CitationsSource
#2Giulio Francolini (UniFI: University of Florence)H-Index: 13
Last. Stefano Maria MagriniH-Index: 25
view all 13 authors...
Abstract Oligometastatic prostate cancer comprises a wide spectrum of conditions, ranging from de novo oligometastatic cancer at diagnosis to oligometastatic castration-resistant disease, which are distinct entities in terms of biology and prognosis. In order to clarify and standardize the clinical role of ablative radiotherapy in oligometastatic prostate cancer, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) formed an expert panel to review the current literature and devel...
14 CitationsSource
#1Giorgio TregliaH-Index: 49
Last. Luca CerianiH-Index: 29
view all 6 authors...
Background: The use of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer (BRPCa) is increasing worldwide. Recently, 18F-labeled PSMA agents have become available. We performed a systematic review and meta-analysis regarding the detection rate (DR) of 18F-labeled PSMA PET/CT in BRPCa to provide evidence-based data in this setting. Methods: A comprehensive literature search of PubMed/MEDLINE, EMB...
31 CitationsSource
Cited By1
Newest
#2Cigdem Soydal (Ankara University)H-Index: 14
Last. Rie von Eyben (Stanford University)H-Index: 23
view all 3 authors...
The study aimed to summarize clinical characteristics associated with Gallium-68-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (68Ga-PSMA PET/CT) scans as patients were restaged for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or external beam radiotherapy (EBRT). Our analyses included multiple cox regression analyses. The study evaluated 95 patients with rising values of PSAs after RP and after EBRT. Sixty 63% of patients ...
Source